ABBV vs JANX

AbbVie Inc. (ABBV) is a well-established mega-cap pharmaceutical company with a robust product portfolio, strong financial health, and a leading position in key therapeutic areas. It excels as a stable dividend payer and a defensive holding. However, its fundamental characteristics, including its immense market capitalization ($397.29B), the mature nature of the pharmaceutical industry, high R&D c...

Janux Therapeutics maintains significant 10x growth potential, underpinned by its innovative TRACTr platform and strategic focus on T-cell engagers for solid tumors and now autoimmune diseases. The Bristol Myers Squibb collaboration provides substantial validation and non-dilutive funding, bolstering its already strong cash position of approximately $1B. Anticipated clinical data readouts througho...